A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3.

Abstract

Activated c-MET has pleiotropic effects on multiple cancer-promoting signaling pathways and may play a critical role in driving tumor cell growth and survival. INCB28060 is a potent and selective c-MET kinase inhibitor that may have therapeutic potential in cancer treatment.

Full Text

• DOI - Clinical cancer research : an official journal of the American Association for Cancer Research (DOI)
• HighWire Press - full-text online

Subjects

• Animals
• Antineoplastic Agents
• Benzamides
• Bicyclo Compounds, Heterocyclic
• Cell Line, Tumor
• Dose-Response Relationship, Drug
• Enzyme Activation
• Female
• Glioblastoma
• Humans
• Mice
• Mice, Nude
• Neoplasms, Experimental
• Phosphorylation
• Protein Kinase Inhibitors
• Proto-Oncogene Proteins c-met
• Receptor Cross-Talk
• Receptor, Epidermal Growth Factor
• Receptor, erbB-3
• Signal Transduction
• Xenograft Model Antitumor Assays

Similar articles

• A Novel Inhibitor of c-Met and VEGF Receptor Tyrosine Kinases with a Broad Spectrum of In Vivo Antitumor Activities. (2013-04-02)
• Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. (2011-02-02)
• An in vivo model of Met-driven lymphoma as a tool to explore the therapeutic potential of Met inhibitors. (2008-04-02)
• Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells. (2008-05-02)
• Enhanced hepatocyte growth factor signaling by type II transforming growth factor-beta receptor knockout fibroblasts promotes mammary tumorigenesis. (2007-05-18)
• Met-induced membrane blebbing leads to amoeboid cell motility and invasion. (2013-05-13)
• TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. (2007-02-06)
• Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET. (2013-04-19)
• Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell death. (2011-03-03)

Authors

• Xiangdong Liu
• Qian Wang
• Gengjie Yang
• Cindy Marando
• Holly K Koblish
• Leslie M Hall
• Jordan S Fridman
• Elham Behshad
• Richard Wynn
• Yu Li
• Jason Boer
• Sharon Diamond
• Chunhong He
• Meizhong Xu
• Jincong Zhuo
• Wenqing Yao
• Robert C Newton
• Peggy A Scherle

Publication date

2011-11-17

Journal

Journal topics

• Neoplasms

Language

Eng.

Copyright

Clinical cancer research : an official journal of the American Association for Cancer Research

Incyte Corporation, Wilmington, Delaware 19880, USA. xliu [at] incyte.com

Release reference

Clin Cancer Res. 2011 Nov;17(22):7127-38

Related books

• Books of Animals
• Books of Antineoplastic Agents
• Books of Benzamides
• Books of Bicyclo Compounds, Heterocyclic
• Books of Cell Line, Tumor
• Books of Dose-Response Relationship, Drug
• Books of Enzyme Activation
• Books of Glioblastoma
• Books of Mice
• Books of Mice, Nude
• Books of Neoplasms
• Books of Neoplasms, Experimental
• Books of Phosphorylation
• Books of Protein Kinase Inhibitors
• Books of Proto-Oncogene Proteins c-met
• Books of Receptor Cross-Talk
• Books of Receptor, Epidermal Growth Factor
• Books of Receptor, erbB-3
• Books of Signal Transduction
• Books of Xenograft Model Antitumor Assays